Expression signatures and roles of microRNAs in inflammatory breast cancer

Qi, Yu; Wang, Xiangyu; Kong, Xiangyi; Zhai, Jie; Fang, Yi; Guan, Xiaoxiang; Wang, Jing

doi:10.1186/s12935-018-0709-6

Cited by 22 publications

(22 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, 55–85% of patients present with positive metastatic lymph node (LN) involvement and up to one-third of patients have distant metastasis at diagnosis [ 4 ]. IBC only accounts for 2–4% of all breast cancer cases, but it is responsible for 7–10% of breast cancer-related deaths [ 3 , 5 ]. IBC patients have poorer survival rates compared with non-IBC patients despite of the presence of multiple improved treatments [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…IBC only accounts for 2–4% of all breast cancer cases, but it is responsible for 7–10% of breast cancer-related deaths [ 3 , 5 ]. IBC patients have poorer survival rates compared with non-IBC patients despite of the presence of multiple improved treatments [ 5 ]. In Egypt, IBC accounts for 11% of the diagnosed breast cancer cases and only 24% of IBC exhibit 4-year survival versus 67% of non-IBC, despite the similar multidisciplinary care given for both diseases [ 4 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory Breast Carcinoma: Elevated microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p Expression as Potential Biomarkers with Diagnostic Value

et al. 2020

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is a rare yet aggressive breast cancer variant, associated with a poor prognosis. The major challenge for IBC is misdiagnosis due to the lack of molecular biomarkers. We profiled dysregulated expression of microRNAs (miRNAs) in primary samples of IBC and non-IBC tumors using human breast cancer miRNA PCR array. We discovered that 28 miRNAs were dysregulated (10 were upregulated, while 18 were underexpressed) in IBC vs. non-IBC tumors. We identified 128 hub genes, which are putative targets of the differentially expressed miRNAs and modulate important cancer biological processes. Furthermore, our qPCR analysis independently verified a significantly upregulated expression of miR-181b-5p, whereas a significant downregulation of miR-200b-3p, miR-200c-3p, and miR-203a-3p was detected in IBC tumors. Receiver operating characteristic (ROC) curves implied that the four miRNAs individually had a diagnostic accuracy in discriminating patients with IBC from non-IBC and that miR-203a-3p had the highest diagnostic value with an AUC of 0.821. Interestingly, a combination of miR-181b-5p, miR-200b-3p, and miR-200c-3p robustly improved the diagnostic accuracy, with an area under the curve (AUC) of 0.897. Intriguingly, qPCR revealed that the expression of zinc finger E box-binding homeobox 2 (ZEB2) mRNA, the putative target of miR-200b-3p, miR-200c-3p, and miR-203a-3p, was upregulated in IBC tumors. Overall, this study identified a set of miRNAs serving as potential biomarkers with diagnostic relevance for IBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Inflammatory Breast Carcinoma: Elevated microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p Expression as Potential Biomarkers with Diagnostic Value

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Qi et al described 5 potential miRNAs as diagnostic molecular biomarkers in IBC (miR-301b, miR-451, miR-15a, miR-342-3p and miR-342-5p), some miRNAs associated with a better (miR-19a, miR-7, miR-324-5p) and with poorer prognosis (miR-21, miR-205). 26 Other studies described the lower expression of miR-26b in IBC than in normal breast tissue and lower expression of miR-205 in IBC compared with non-IBC. Lower expression of both, miR-26b and miR-205, was associated with shorter distant metastasis-free survival and overall survival.…”

Section: Tumor-associated Biomarkersmentioning

confidence: 96%

<p>Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility</p>

Dobiášová

Mego

2020

BCTT

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is a rare and highly aggressive subtype of advanced breast cancer. The aggressive behavior, resistance to chemotherapy, angiogenesis, and high metastatic potential are key intrinsic characteristics of IBC caused by many specific factors. Pathogenesis and behavior of IBC are closely related to tumor surrounding inflammatory and immune cells, blood vessels, and extracellular matrix, which are all components of the tumor microenvironment (TME). The tumor microenvironment has a crucial role in the local immune r09esponse. The communication between intrinsic and extrinsic components of IBC and the abundance of cytokines and chemokines in the TME strongly contribute to the aggressiveness and high angiogenic potential of this tumor. Critical modes of interaction are cytokine-mediated communication and direct intercellular contact between cancer cells and tumor microenvironment with a variety of pathway crosstalk. This review aimed to summarize current knowledge of predictive and prognostic biomarkers in IBC.

show abstract

“…MiRNA is a non-coding RNA with about 22 nucleotides in size [9][10][11] and can participate in the regulation of cell progression in various cancer. 9,[12][13][14] Besides, research unclosed that miRNA was closely linked to the drug resistance of cancer.…”

Section: Introductionmentioning

confidence: 99%

<p>Circ_0110805 Knockdown Enhances Cisplatin Sensitivity and Inhibits Gastric Cancer Progression by miR-299-3p/ENDOPDI Axis</p>

Yang

Zhang

Guan

2020

OTT

View full text Add to dashboard Cite

Background: Gastric cancer is a prevalent primary stomach tumor. Cisplatin is frequently used to treat gastric cancer. However, the resistance of cisplatin in gastric cancer often occurs, which brings a heavy burden to gastric cancer treatment. Methods: In this study, we revealed a novel underlying mechanism about cisplatin-resistant effect in gastric cancer. A Cell Counting Kit-8 (CCK-8) cell viability assay and a xenograft model were performed to evaluate the function of circRNA in the cisplatin resistance of gastric cancer. Results: Compared with control groups, we observed that circ_0110805 was highly expressed, the mRNA and protein expression levels of ENDOPDI were dramatically upregulated, and the expression of miR-299-3p was significantly downregulated in gastric cancer cells, cisplatin-resistant gastric cancer tissues or cells. Functionally, circ_0110805 knockdown improved cisplatin sensitivity, induced cell apoptosis, whereas repressed cell viability, migration and invasion in AGS/DDP and HGC-27/DDP cells, which was reversed by miR-299-3p inhibitor. Additionally, ENDOPDI overexpression hindered the effects of miR-299-3p on cisplatin sensitivity and gastric cancer progression. Circ_0110805 knockdown enhanced cisplatin sensitivity in vivo. Mechanistically, circ_0110805 acted as a sponge of miR-299-3p and its targeted ENDOPDI. Conclusion: We showed that circ_0110805 knockdown increased the sensitivity of gastric cancer to cisplatin, which also repressed gastric cancer progression by sponging miR-299-3p to downregulate ENDOPDI expression. It might provide a new insight for future studying cisplatin-resistant gastric cancer.

show abstract

Expression signatures and roles of microRNAs in inflammatory breast cancer

Cited by 22 publications

References 86 publications

Inflammatory Breast Carcinoma: Elevated microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p Expression as Potential Biomarkers with Diagnostic Value

Inflammatory Breast Carcinoma: Elevated microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p Expression as Potential Biomarkers with Diagnostic Value

<p>Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility</p>

<p>Circ_0110805 Knockdown Enhances Cisplatin Sensitivity and Inhibits Gastric Cancer Progression by miR-299-3p/ENDOPDI Axis</p>

Contact Info

Product

Resources

About